Nurix Therapeutics, INC Schedule 13G passive stakes

Redmile Group, LLC, Jeremy C. Green, and RedCo II Offshore SPV LLC have updated their beneficial ownership filings for Nurix Therapeutics, Inc., collectively holding 8.1% and 3.5% of the common stock.

Vestal Point Capital, LP, through its managed funds, has disclosed beneficial ownership of 8,050,000 shares, representing 7.8% of Nurix Therapeutics, Inc. common stock.

Rubric Capital Management LP and David Rosen have jointly filed a Schedule 13G, reporting beneficial ownership of 7,227,778 shares, representing 6.96% of Nurix Therapeutics' common stock as of June 30, 2026.

Deep Track Capital, LP, along with affiliated entities, has disclosed a beneficial ownership of 7.45% of Nurix Therapeutics, Inc. common stock as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of over 5.03% of Nurix Therapeutics Inc. common stock as of June 30, 2026.

Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 6.3% beneficial ownership stake in Nurix Therapeutics, Inc.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 6,345,244 shares, representing 6.17% of Nurix Therapeutics, Inc.'s common stock as of March 31, 2026.

FMR LLC, through its affiliates, has reported beneficial ownership of 5.4% of Nurix Therapeutics Inc.'s common stock as of March 31, 2026.

Redmile Group has completed an internal reorganization of its holdings in Nurix Therapeutics, maintaining a 9.9% stake while shifting direct ownership to a new subsidiary.

The Vanguard Group has reported a 0% beneficial ownership in Nurix Therapeutics Inc. common stock following an internal realignment.

Commodore Capital LP and Commodore Capital Master LP have amended their beneficial ownership in Nurix Therapeutics, Inc., reporting a 4.9% stake as of September 30, 2025.

FMR LLC and Abigail P. Johnson disclose a 4.1% beneficial ownership in Nurix Therapeutics Inc. common stock in an amended Schedule 13G filing.

FMR LLC and Abigail P. Johnson reported an 11.5% beneficial ownership stake in Nurix Therapeutics Inc. common stock as of September 30, 2025.

Deep Track Capital, LP, along with its affiliated entities, has reported a beneficial ownership of 7.21% of Nurix Therapeutics, Inc.'s common stock as of March 31, 2025.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a reduced beneficial ownership of 4.18% in Nurix Therapeutics, Inc. as of March 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 13.4% of Nurix Therapeutics Inc.'s common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting an 8.2% passive beneficial ownership stake in Nurix Therapeutics, Inc. as of March 31, 2025.

Deep Track Capital, along with its affiliates Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a passive beneficial ownership of 5.44% in Nurix Therapeutics, Inc.'s common stock.

Commodore Capital LP and Commodore Capital Master LP have jointly reported a 5.1% beneficial ownership stake in Nurix Therapeutics, Inc., holding 3,850,000 shares of common stock.

Deep Track Capital, LP and its affiliates have reported a reduction in their beneficial ownership of Nurix Therapeutics, Inc. common stock to 4.24% as of December 31, 2024, no longer requiring a Schedule 13G filing.

ARK Investment Management LLC has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in Nurix Therapeutics Inc. as of September 30, 2024.